To view current and resolved drug shortages and discontinuations reported to FDA click here.
AstraZeneca Voluntarily Withdraws LYNPARZA’s Indication for Treatment of Adult Patients with Deleterious/Suspected Deleterious gBRCAm Advanced Ovarian Cancer, Treated w/ 3 or More Prior Lines of Chemo
The withdrawal of this indication has no impact on LYNPARZA’s maintenance indications and other approved indications.
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!